Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies with rubidazone.

R S Benjamin, M J Keating, K D Swenerton

    Cancer Treatment Reports
    |May 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.

    Gynecologic oncology·2011
    Same author

    Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
    Same author

    Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
    Same author

    Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

    Gynecologic oncology·2005
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Rubidazone shows significant antileukemic activity in acute leukemia patients, with optimal dosing at 450 mg/m2. However, its efficacy in solid tumors is limited, and cardiac toxicity is a concern in patients with prior anthracycline exposure.

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Rubidazone is an investigational chemotherapeutic agent.
    • Previous studies suggested potential antileukemic activity.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of rubidazone in patients with acute leukemia and solid tumors.
    • To determine optimal dosing and identify dose-limiting toxicities.

    Main Methods:

    • Phase I-II and Phase II clinical trials involving 133 patients (94 with acute leukemia, 39 with solid tumors).
    • Rubidazone administered alone or in combination with other chemotherapeutic agents.
    • Dose escalation and evaluation of treatment response and adverse events.

    Main Results:

    Related Experiment Videos

    • Substantial antileukemic activity observed, with complete remission rates of 42% in acute myelogenous leukemia and 70% in acute lymphocytic leukemia.
    • Combination therapy in older acute leukemia patients achieved 50% complete remission.
    • Limited efficacy in solid tumors, with best responses in period carcinoma; no response in thyroid or breast cancer.
    • Dose-limiting toxicities included mucositis (leukemia) and myelosuppression (solid tumors).
    • Cardiac toxicity (congestive heart failure) occurred at cumulative doses in patients with prior anthracycline exposure.

    Conclusions:

    • Rubidazone is an active antileukemic agent, particularly effective in combination regimens for older patients.
    • Rubidazone demonstrates less activity compared to Adriamycin in solid tumors.
    • Careful monitoring for cardiac toxicity is recommended, especially in patients with a history of anthracycline treatment.